{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:31:29Z","timestamp":1792679489008,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis are chronic progressive immune-mediated rheumatic diseases (IMRD) that can cause a progressive disability and joint deformation and thus can impact in healthcare resource utilization (HCRU) and costs. The main outcome of the study was to assess the effect of non-persistence to treatment with subcutaneous tumor necrosis factor-alpha inhibitors (SC-TNFis) on HCRU costs in na\u00efve patients with IMRD who started treatment with adalimumab, etanercept, golimumab or certolizumab pegol during 12\u00a0months after initiation of treatment. The impact of persistence and non-persistence of SC-TNFis on HCRU costs was compared between 12\u00a0months before and 12\u00a0months after initiating SC-TNFis. Persistence was defined as the duration of time from initiation to discontinuation of therapy. The study was conducted in an acute care teaching hospital in Barcelona, Spain. Data for the period between 2015 and 2018 were extracted from the hospital cost management control database. HCRU costs comprised outpatient care, outpatient specialized rheumatology care, in-patient care, emergency care, laboratory testing and other non-biological therapies. The study population included 110 na\u00efve SC-TNFis patients, divided into the cohorts of persistent (<jats:italic>n<\/jats:italic> = 85) and non-persistent (<jats:italic>n<\/jats:italic> = 25) patients. Fifty-six percent of patients were women, with a mean (standard deviation) age of 47.6 (14.8) years. Baseline clinical features and HCRU costs over the 12\u00a0months before the index prescription were similar in the two study groups. Before-and-after differences in mean (standard deviation) HCRU costs were significantly higher in the non-persistence group as compared to the persistence group for outpatient rheumatology care (\u20ac110.90 [234.56] vs. \u20ac20.80 [129.59], <jats:italic>p<\/jats:italic> = 0.023), laboratory testing (\u2212\u20ac193.99 [195.88] vs. \u2212\u20ac241.3 [217.88], <jats:italic>p<\/jats:italic> = 0.025), other non-biological drugs (\u20ac3849.03 [4046.14] vs. \u2212\u20ac10.90 [157.42], <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and total costs (\u20ac3268.90 [4821.55] vs. \u2212\u20ac334.67 (905.44), <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Treatment persistence with SC-TNFis may be associated with HCRU cost savings in na\u00efve IMRD patients. Prescribing SC-TNFis with the best long-term persistence is beneficial.<\/jats:p>","DOI":"10.3389\/fphar.2021.752879","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:44:40Z","timestamp":1638366280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Nuria","family":"Carballo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Garcia-Alz\u00f3rriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ferr\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Navarrete-Rouco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Dur\u00e1n-Jord\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Monfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Cots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e015872","DOI":"10.1136\/bmjopen-2017-015872","article-title":"Adherence and Dosing Interval of Subcutaneous Antitumour Necrosis Factor Biologics Among Patients with Inflammatory Arthritis: Analysis from a Canadian Administrative Database","volume":"7","author":"Bhoi","year":"2017","journal-title":"BMJ Open"},{"key":"B2","first-page":"192","article-title":"Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis after a Change in Targeted Therapy","volume":"11","author":"Bonafede","year":"2018","journal-title":"Am. Health Drug Benefits"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1185\/03007990902896386","article-title":"Trends in RA Patients' Adherence to Subcutaneous Anti-TNF Therapies and Costs","volume":"25","author":"Borah","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","article-title":"Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA","volume":"34","author":"Chastek","year":"2017","journal-title":"Adv. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","article-title":"Treatment Choices, Preferences and Decision-Making by Patients with Rheumatoid Arthritis","volume":"6","author":"Chilton","year":"2008","journal-title":"Musculoskeletal Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication Compliance and Persistence: Terminology and Definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.18553\/jmcp.2015.21.4.318","article-title":"Cost and Effectiveness of Biologics for Rheumatoid Arthritis in a Commercially Insured Population","volume":"21","author":"Curtis","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00296-017-3825-z","article-title":"Second-line Treatment Persistence and Costs Among Patients with Immune-Mediated Rheumatic Diseases Treated with Subcutaneous TNF-Alpha Inhibitors","volume":"37","author":"Dal\u00e9n","year":"2017","journal-title":"Rheumatol. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","article-title":"Treatment Persistence Among Patients with Immune-Mediated Rheumatic Disease Newly Treated with Subcutaneous TNF-Alpha Inhibitors and Costs Associated with Non-persistence","volume":"36","author":"Dal\u00e9n","year":"2016","journal-title":"Rheumatol. Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00296-018-4177-z","article-title":"Factors Associated with Long-Term Retention of Treatment with Golimumab in a Real-World Setting: an Analysis of the Spanish BIOBADASER Registry","volume":"39","author":"Hernandez","year":"2019","journal-title":"Rheumatol. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","article-title":"Economic burden of Rheumatoid Arthritis: a Systematic Review of Literature in Biologic Era","volume":"79","author":"Hsieh","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3899\/jrheum.110901","article-title":"Socioeconomic burden of Immune-Mediated Inflammatory Diseases-Ffocusing on Work Productivity and Disability","volume":"88","author":"Jacobs","year":"2011","journal-title":"J. Rheumatol. Suppl."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2169\/internalmedicine.53.2834","article-title":"A Paradigm Shift in Rheumatoid Arthritis over the Past Decade","volume":"53","author":"Kaneko","year":"2014","journal-title":"Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"689609","DOI":"10.3389\/fmed.2021.689609","article-title":"Comparison of Retention Rates between Tumor Necrosis Factor-\u03b1 Inhibitors in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry","volume":"8","author":"Kim","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.18553\/jmcp.2018.24.7.654","article-title":"Evaluating the Effect of Treatment Persistence on the Economic burden of Moderate to Severe Psoriasis And\/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population","volume":"24","author":"Lee","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1524-4733.2010.00764.x","article-title":"Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis","volume":"13","author":"Li","year":"2010","journal-title":"Value Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/01.mlr.0000204257.25875.04","article-title":"The Indirect Costs of Arthritis Resulting from Unemployment, Reduced Performance, and Occupational Changes while at Work","volume":"44","author":"Li","year":"2006","journal-title":"Med. Care"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e027456","DOI":"10.1136\/bmjopen-2018-027456","article-title":"Real-world Treatment Persistence of Golimumab in the Management of Immune-Mediated Rheumatic Diseases in Europe: a Systematic Literature Review","volume":"9","author":"Luttropp","year":"2019","journal-title":"BMJ Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment Response and Drug Retention Rates in 24 195 Biologic-Na\u00efve Patients with Axial Spondyloarthritis Initiating TNFi Treatment: Routine Care Data from 12 Registries in the EuroSpA Collaboration","volume":"78","author":"\u00d8rnbjerg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/rheumatology\/39.suppl_2.3","article-title":"Epidemiology of Rheumatic Diseases","volume":"39","author":"Sangha","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40801-018-0139-8","article-title":"Persistence with Biological Disease-Modifying Antirheumatic Drugs and its Associated Resource Utilization and Costs","volume":"5","author":"Sruamsiri","year":"2018","journal-title":"Drugs Real World Outcomes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/PPA.S119808","article-title":"Persistence and Costs with Subcutaneous TNF-Alpha Inhibitors in Immune-Mediated Rheumatic Disease Stratified by Treatment Line","volume":"11","author":"Svedbom","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.18773\/austprescr.2017.050","article-title":"Encouraging Adherence to Long-Term Medication","volume":"40","author":"Usherwood","year":"2017","journal-title":"Aust. Prescr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.berh.2018.11.002","article-title":"Epidemiology of Rheumatic and Musculoskeletal Diseases","volume":"32","author":"Verstappen","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kel369","article-title":"Patient Preferences in Choosing Anti-TNF Therapies-R1","volume":"45","author":"Williams","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/rheumatology\/key099","article-title":"The Impact of Non-persistence on the Direct and Indirect Costs in Patients Treated with Subcutaneous Tumour Necrosis Factor-Alpha Inhibitors in Germany","volume":"57","author":"Ziegelbauer","year":"2018","journal-title":"Rheumatology (Oxford)"}],"updated-by":[{"DOI":"10.3389\/fphar.2022.867017","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.752879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:21:03Z","timestamp":1646648463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.752879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":26,"alternative-id":["10.3389\/fphar.2021.752879"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.752879","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fphar.2022.867017","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"article-number":"752879"}}